Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06921850 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa

StatusActive, Not Recruiting
PhasePhase 3
Started2025-04-07
View on ClinicalTrials.gov ↗

Amendment history

2026-09-10
Study Status v21
Re-verified, no change to tracked fields
2026-07-30
Study Status, Study Design, Contacts/Locations v20
Enrollment closed, study ongoing
Enrollment targetestimated 40→confirmed 43
Study sitesdetails revised at 18 of 18 sites
2026-07-16
Study Status, Contacts/Locations v19
Study sitesdetails revised at 1 of 18 sites
2026-06-18
Study Status, Contacts/Locations v18
Study sitesdetails revised at 1 of 18 sites
2026-06-04
Study Status, Contacts/Locations v17
Study sitesdetails revised at 1 of 18 sites
Show 16 earlier versions
2026-03-26
Study Status, Contacts/Locations v16
Study sites17→18
2026-03-18
Study Status v15
Primary completion date2027-03-19→2026-12-21
Completion date2029-05-30→2029-03-06
2026-02-23
Study Status, Contacts/Locations v14
Study sites16→17
2025-12-04
Study Status, Contacts/Locations v13
Study sites15→16
2025-11-20
Study Status, Contacts/Locations v12
Study sites14→15
2025-10-23
Study Status, Contacts/Locations v11
Study sites13→14
2025-10-09
Study Status, Contacts/Locations v10
Study sites12→13
2025-09-25
Study Status, Contacts/Locations v9
Study sites10→12
2025-09-11
Study Status, Contacts/Locations v8
Study sites7→10
2025-08-14
Study Status, Contacts/Locations v7
Study sitesdetails revised at 1 of 7 sites
2025-07-17
Study Status, Contacts/Locations v6
Study sites6→7
2025-07-03
Study Status, Contacts/Locations v5
Study sitesdetails revised at 1 of 6 sites
2025-06-17
Study Status v4
Primary completion date2028-07-17→2027-03-19
Completion date2030-11-11→2029-05-30
2025-05-22
Study Status, Contacts/Locations v3
Study sitesdetails revised at 1 of 6 sites
2025-05-09
Study Status, Contacts/Locations v2
Study sites5→6
2025-04-29
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-04-30→confirmed 2025-04-07
Study sites0→5
2025-04-03
Original filing
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Trial Details
NCT Number NCT06921850
Lead Sponsor UCB Biopharma SRL
Conditions Hidradenitis Suppurativa
Enrollment 43 participants
Start Date 2025-04-07
Primary Completion 2026-12-21 (estimated)
Study Completion 2029-03-06 (estimated)
Updated on ClinicalTrials.gov 2026-09-25